LYRICA (pregabalin) by Teva is 2 -delta site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues. First approved in 2004.
Drug data last refreshed 16h ago · AI intelligence enriched 19h ago
LYRICA (pregabalin) is an oral small-molecule anticonvulsant that binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system. It reduces pro-nociceptive neurotransmitter release in the spinal cord and modulates descending pain pathways to treat neuropathic pain, fibromyalgia, and seizure disorders. Pregabalin does not directly bind GABA receptors despite its structural similarity to GABA, instead working through calcium channel modulation and indirect effects on monoamine neurotransmission.
Neuropathic pain market penetration remains strong with 75K+ annual claims, but approaching LOE signals transition from growth defense to generic competition management and cost optimization initiatives.
2 -delta site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues. Although the mechanism of action of pregabalin has not been fully elucidated, results with genetically modified mice and with compounds structurally related to pregabalin (such as gabapentin)…
Worked on LYRICA at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Phase 2a Study Comparing the Efficacy, Safety and Tolerability of Pregabalin Eye Drops Comparing With Timolol Eye Drops in Adults With Glaucoma or High Eye Pressure.
Pharmacokinetics of Y-4 Tablets With Pregabalin Capsules and Riluzole Tablets in U.S. Healthy Participants
Efficacy and Safety of Pregabalin/Tizanidine vs. Pregabalin in Patients With Fibromyalgia
Pharmacokinetics of Y-4 Tablets With Pregabalin Capsules and Riluzole Tablets in Chinese Healthy Subject
Pharmacodynamic Study of 300mg Pregabalin vs Placebo in Healthy Male Adults
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on LYRICA at this lifecycle stage means executing defensive commercial strategy against generic erosion and securing formulary access through payer contracting and value-based positioning. Career growth lies in managed care negotiation, specialty channel development, and patient retention rather than new indication launches.